What did Cowen & Co. do in the March 9, 2026 DNTH analyst rating update?

On March 9, 2026 Cowen & Co. reiterated a **Buy** on Dianthus Therapeutics and called it a “prime takeout target.” The note was a maintenance action affirming prior positive coverage and potential M&A interest.

What price target did Oppenheimer set in the DNTH analyst rating note?

Oppenheimer maintained an **Outperform** on March 9, 2026 and raised its price target to **$145**, signaling higher upside expectations based on its valuation model.

How should investors use the DNTH analyst rating information?

Investors should treat the DNTH analyst rating as one input among fundamentals, trial milestones, and cash runway. Positive ratings support a bullish case but do not remove biotech execution risks.

What does Meyka AI’s B+ grade mean for DNTH after the analyst notes?

Meyka AI rates DNTH **B+**, combining analyst consensus, sector performance, financial growth, and benchmark comparisons. The grade indicates constructive outlook but recognizes inherent biotech risks.

Analyst Ratings

Cowen Maintains Buy on DNTH and Oppenheimer Keeps Outperform March 2026

ByHuzaifa Zahoor March 10, 2026March 10, 2026

On March 9, 2026 the DNTH analyst rating update saw Cowen & Co. reiterate Buy and Oppenheimer maintain Outperform while raising its price target to $145. The dual notes arrived within hours and reflect continued analyst interest in Dianthus Therapeutics, Inc. (DNTH). Investors should weigh the firm endorsements and Oppenheimer’s higher $145 price target against short‑term stock moves and the company’s market capitalization of $2,867,066,525. Meyka AI provides this AI‑powered market analysis to clarify what the ratings mean for shareholders and traders.